Literature DB >> 29630018

Prescription and Other Medication Use in Pregnancy.

David M Haas1, Derek J Marsh, Danny T Dang, Corette B Parker, Deborah A Wing, Hyagriv N Simhan, William A Grobman, Brian M Mercer, Robert M Silver, Matthew K Hoffman, Samuel Parry, Jay D Iams, Steve N Caritis, Ronald J Wapner, M Sean Esplin, Michal A Elovitz, Alan M Peaceman, Judith Chung, George R Saade, Uma M Reddy.   

Abstract

OBJECTIVE: To characterize prescription and other medication use in a geographically and ethnically diverse cohort of women in their first pregnancy.
METHODS: In a prospective, longitudinal cohort study of nulliparous women followed through pregnancy from the first trimester, medication use was chronicled longitudinally throughout pregnancy. Structured questions and aids were used to capture all medications taken as well as reasons they were taken. Total counts of all medications taken including number in each category and class were captured. Additionally, reasons the medications were taken were recorded. Trends in medications taken across pregnancy and in the first trimester were determined.
RESULTS: Of the 9,546 study participants, 9,272 (97.1%) women took at least one medication during pregnancy with 9,139 (95.7%) taking a medication in the first trimester. Polypharmacy, defined as taking at least five medications, occurred in 2,915 (30.5%) women. Excluding vitamins, supplements, and vaccines, 73.4% of women took a medication during pregnancy with 55.1% taking one in the first trimester. The categories of drugs taken in pregnancy and in the first trimester include the following: gastrointestinal or antiemetic agents (34.3%, 19.5%), antibiotics (25.5%, 12.6%), and analgesics (23.7%, 15.6%, which includes 3.6%; 1.4% taking an opioid pain medication).
CONCLUSION: In this geographically and ethnically diverse cohort of nulliparous pregnant women, medication use was nearly universal and polypharmacy was common. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01322529.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29630018      PMCID: PMC5912972          DOI: 10.1097/AOG.0000000000002579

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  24 in total

1.  Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008.

Authors:  Allen A Mitchell; Suzanne M Gilboa; Martha M Werler; Katherine E Kelley; Carol Louik; Sonia Hernández-Díaz
Journal:  Am J Obstet Gynecol       Date:  2011-04-22       Impact factor: 8.661

2.  Increasing pregnancy-related use of prescribed opioid analgesics.

Authors:  Richard A Epstein; William V Bobo; Peter R Martin; James A Morrow; Wei Wang; Rameela Chandrasekhar; William O Cooper
Journal:  Ann Epidemiol       Date:  2013-08       Impact factor: 3.797

3.  Use of over-the-counter medications and herbal remedies in pregnancy.

Authors:  Jerrie S Refuerzo; Sean C Blackwell; Robert J Sokol; Lorraine Lajeunesse; Katherine Firchau; Michael Kruger; Yoram Sorokin
Journal:  Am J Perinatol       Date:  2005-08       Impact factor: 1.862

4.  National patterns of medication use during pregnancy.

Authors:  Euni Lee; Mary K Maneno; Leah Smith; Sheila R Weiss; Ilene H Zuckerman; Anthony K Wutoh; Zhenyi Xue
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-08       Impact factor: 2.890

5.  Getting to safer and smarter medication use during pregnancy.

Authors:  Jason G Umans; Marshall D Lindheimer
Journal:  Am J Obstet Gynecol       Date:  2014-12-30       Impact factor: 8.661

6.  The current state of therapeutic drug trials in pregnancy.

Authors:  S Endicott; D M Haas
Journal:  Clin Pharmacol Ther       Date:  2012-08       Impact factor: 6.875

7.  Prevalence of illicit drug use in pregnant women in a Wisconsin private practice setting.

Authors:  Charles W Schauberger; Emily J Newbury; Jean M Colburn; Mohammed Al-Hamadani
Journal:  Am J Obstet Gynecol       Date:  2014-03-13       Impact factor: 8.661

8.  Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems.

Authors:  Kirsten K Viktil; Hege S Blix; Tron A Moger; Aasmund Reikvam
Journal:  Br J Clin Pharmacol       Date:  2006-08-30       Impact factor: 4.335

9.  The Most Commonly Dispensed Prescription Medications Among Pregnant Women Enrolled in the U.S. Medicaid Program.

Authors:  Kristin Palmsten; Sonia Hernández-Díaz; Christina D Chambers; Helen Mogun; Sophia Lai; Todd P Gilmer; Krista F Huybrechts
Journal:  Obstet Gynecol       Date:  2015-09       Impact factor: 7.661

Review 10.  Interventions for nausea and vomiting in early pregnancy.

Authors:  Anne Matthews; David M Haas; Dónal P O'Mathúna; Therese Dowswell
Journal:  Cochrane Database Syst Rev       Date:  2015-09-08
View more
  21 in total

1.  Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir.

Authors:  Xiaomei I Liu; Jeremiah D Momper; Natella Rakhmanina; John N van den Anker; Dionna J Green; Gilbert J Burckart; Brookie M Best; Mark Mirochnick; Edmund V Capparelli; André Dallmann
Journal:  J Clin Pharmacol       Date:  2019-09-06       Impact factor: 3.126

Review 2.  Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women.

Authors:  Shreya Patel; Manish Kumar; Craig J Beavers; Saad Karamat; Fawaz Alenezi
Journal:  Curr Atheroscler Rep       Date:  2022-07-21       Impact factor: 5.967

3.  Racial/Ethnic Differences in Prenatal Supplement and Medication Use in Low-Risk Pregnant Women.

Authors:  Yassaman Vafai; Edwina H Yeung; Rajeshwari Sundaram; Melissa M Smarr; Nicole Gerlanc; William A Grobman; Daniel Skupski; Edward K Chien; Stefanie N Hinkle; Roger B Newman; Deborah A Wing; Angela C Ranzini; Anthony Sciscione; Jagteshwar Grewal; Cuilin Zhang; Katherine L Grantz
Journal:  Am J Perinatol       Date:  2020-10-08       Impact factor: 3.079

4.  Pregnancy outcomes and anxiety in nulliparous women.

Authors:  Lauren A Gimbel; Nathan R Blue; Amanda A Allshouse; Robert M Silver; Bruce Gimbel; William A Grobman; David M Haas; Hyagriv N Simhan; Brian M Mercer; Tamera Hatfield
Journal:  J Matern Fetal Neonatal Med       Date:  2021-11-07

5.  Prevalence and safety of prescription medicine use during pregnancy in the Republic of Suriname in the year 2017: a pharmacoepidemiological analysis.

Authors:  Vinoj H Sewberath Misser; Arti Shankar; Ashna Hindori-Mohangoo; Jeffrey Wickliffe; Maureen Lichtveld; Dennis R A Mans
Journal:  Adv Pharmacoepidemiol Drug Saf       Date:  2021-09-20

6.  Drug Positivity Findings from a Universal Umbilical Cord Tissue Drug Analysis Program in Appalachia.

Authors:  Panitan Yossuck; Danyel H Tacker
Journal:  J Appl Lab Med       Date:  2021-01-12

7.  Profile of Reported Alcohol, Tobacco, and Recreational Drug Use in Nulliparous Women.

Authors:  David M Haas; Brianna Mahnke; Ziyi Yang; David Guise; Joanne Daggy; Hyagriv N Simhan; Robert M Silver; William A Grobman; Ronald J Wapner; Joshua Makhoul; Samuel Parry; Brian M Mercer; George R Saade
Journal:  Obstet Gynecol       Date:  2020-06       Impact factor: 7.623

8.  The Italian Network for Monitoring Medication Use During Pregnancy (MoM-Net): Experience and Perspectives.

Authors:  Valeria Belleudi; Filomena Fortinguerra; Francesca R Poggi; Serena Perna; Renata Bortolus; Serena Donati; Antonio Clavenna; Anna Locatelli; Marina Davoli; Antonio Addis; Francesco Trotta
Journal:  Front Pharmacol       Date:  2021-06-23       Impact factor: 5.810

9.  Prediction of Pregnancy-Induced Changes in Secretory and Total Renal Clearance of Drugs Transported by Organic Anion Transporters.

Authors:  Jinfu Peng; Mayur K Ladumor; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2021-07-27       Impact factor: 3.579

10.  Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997-2011.

Authors:  Craig Hansen; Tania A Desrosiers; Kathy Wisniewski; Matthew J Strickland; Martha M Werler; Suzanne M Gilboa
Journal:  Birth Defects Res       Date:  2020-07-13       Impact factor: 2.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.